Agenus launches SaponiQx subsidiary

By The Science Advisory Board staff writers

September 10, 2021 -- Agenus is launching a new subsidiary dedicated to novel adjuvant discovery and vaccine design, the company announced.

The subsidiary, SaponiQx, is building a platform that aims to deliver sustainable manufacturing approaches and a secure supply of known adjuvants. In addition, the platform is designed to discover novel adjuvants and develop vaccines that use optimized antigen-adjuvant pairings, Agenus said.

The subsidiary is collaborating with Ginkgo Bioworks and using Ginkgo's metabolic engineering for novel adjuvant discovery.

Copyright © 2021

Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter